The big health industry is becoming a new policy slogan. The national high-level officials held a meeting to review and approve the “Healthy China 2030” planning outline. We will relax market access, encourage social capital and overseas capital to invest in the health service industry in various forms in accordance with the law, and accelerate the implementation of policy dividends for socially-run medical institutions in social security fixed-point and specialist construction, and open up the health service industry. Long-term growth space.

In the medical and health industry, we are welcoming the development opportunities across the board. How will investment institutions integrate and deploy horizontally and vertically in the industry chain? Shenzhen, a shared investment management partner focused on medical health and connected innovation, can say that he has a voice.

At the recent China Investment Annual Conference of the China Investment Group held in Shenzhen, the Chinese-funded VC organization established in 2007 won a number of awards from investment institutions, investment projects and investors related to the medical and health field, such as the 2016 medical device field. Investment institutions Top10 and 2016 annual bio-medical investment institutions Top10 two institutional awards. The two venture companies, Maipu Medical and Pan-Family, have been selected into the top ten cases in the field of medical devices and biomedicine.

Share investment management partner

Share investment management partner Huang, vice versa, this time was also named 2016 Top 10 investors and the best investor in the medical field Top10. A few days ago, he accepted an exclusive interview with Nanfang Daily, analyzed the current investment opportunities in the medical and health industry, the key factors of venture capital investment, and elaborated on the thinking and specific investment ideas of sharing investment in precision medical fields.

The health care industry was developing at the time

“Ma Yun said that the richest man in the future will definitely be in the medical and health industry. Why does he say this?” Huang said that the scale of China’s medical health market has exceeded 4 trillion in 2015, and it is expected to reach 80,000 in the next five years. Billion-10 trillion. " Such a huge market, such a high-speed growth, of course, should be a hot spot for capital chasing."

Huang said that China has now surpassed Japan to become the world's second largest economy, but China's per capita medical expenditure as a share of GDP, the official statistics are only ranked 12th in the world. This shows that China's per capita medical level and economic status are not commensurate, and it just shows that China's medical expenditures still have a lot of room for growth.

"From the time and place to see and see, now the medical and health industry is just the right time." Huang said, from the perspective of national policies, the country has promoted mass entrepreneurship and innovation in these years, especially for new drug research and development, device innovation, and biology. Technology has already introduced a large number of support policies, and a large number of new parks have been built in various places, which will greatly promote the development of the medical and health industry.

He pointed out that in the north, Guangzhou, Shenzhen and Suzhou, the effect of medical health clusters has been formed. For example, in Shenzhen, a cluster of biotechnology led by Huada has been formed, and a cluster of medical devices led by Mindray has been formed; in Suzhou, a cluster of biotechnology and IVD detection, including high-tech zones and Suzhou Industrial Park, has been formed; Shanghai Zhangjiang Medical Park has formed a cluster of new drugs and equipment; in Beijing, it has formed an industrial cluster with biotechnology, new drug research and development, and comprehensive equipment.

Huang said that the support of China's capital market has brought opportunities for startups in the medical and health fields. In the past, the A-share market first required financial indicators, while for innovative companies, especially new drug research and development, biotechnology, it may face a long-term stage of no cash flow. The launch of the New Third Board is a great encouragement and support for such innovative companies.

"Many people think that the New Third Board has no value, I don't agree with it." Huang said, for example, a biopharmaceutical company in Shanghai Zhangjiang Medical Park was listed in August 2014, and in February of 2015, a total of 6 months. Times, each time more than 1 billion, the valuation reached more than 4 billion. “Everyone thinks, if there is no new three board, where can such a company finance?”

He believes that the New Third Board is somewhat like the US Nasdaq. It has formed a step-by-step support for high-risk technology innovation companies, providing an exit channel for VC investment in biomedical innovation companies. At present, in the United States, Nasdaq, the second phase of the new drug evaluation of the second phase can reach 1.7 billion US dollars, the highest value of the new phase of the clinical phase III drug can reach more than 7 billion US dollars. "I believe that China will see such a situation in the future."

Air Hose Reel

Air Hose Reel,Mini Air Hose Reel,Air Compressor Hose Reel,Industrial Air Hose Reel

NINGBO QIKAI ENVIRONMENTAL TECHNOLOGY CO.,LTD , https://www.water-hose-reel.com